Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Patient-reported outcomes are worse for progressive-onset multiple sclerosis than relapse-onset multiple sclerosis, particularly early in the disease process.

Zhang Y, Taylor BV, Simpson S Jr, Blizzard L, van der Mei I.

Eur J Neurol. 2018 Aug 22. doi: 10.1111/ene.13786. [Epub ahead of print]

PMID:
30133059
2.

What is the actual prevalence of migraine?

Yeh WZ, Blizzard L, Taylor BV.

Brain Behav. 2018 Jun;8(6):e00950. doi: 10.1002/brb3.950. Epub 2018 May 2.

3.

Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset.

Tao C, Simpson S Jr, Taylor BV, Blizzard L, Lucas RM, Ponsonby AL, Broadley S; AusLong/Ausimmune Investigators Group, van der Mei I.

Front Neurol. 2018 Jun 8;9:418. doi: 10.3389/fneur.2018.00418. eCollection 2018.

4.

Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.

Chen J, Taylor BV, Blizzard L, Simpson S Jr, Palmer AJ, van der Mei IAF.

J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1200-1207. doi: 10.1136/jnnp-2018-318228. Epub 2018 Jun 19.

PMID:
29921609
5.

Search for a prognostic biomarker in multiple sclerosis: a step in the right direction?

Taylor BV.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1015. doi: 10.1136/jnnp-2018-318326. Epub 2018 May 15. No abstract available.

PMID:
29764926
6.

Genotype and Phenotype in Multiple Sclerosis-Potential for Disease Course Prediction?

Jokubaitis VG, Zhou Y, Butzkueven H, Taylor BV.

Curr Treat Options Neurol. 2018 Apr 24;20(6):18. doi: 10.1007/s11940-018-0505-6. Review.

PMID:
29687310
7.

Genomic Effects of the Vitamin D Receptor: Potentially the Link between Vitamin D, Immune Cells, and Multiple Sclerosis.

Lu M, Taylor BV, Körner H.

Front Immunol. 2018 Mar 12;9:477. doi: 10.3389/fimmu.2018.00477. eCollection 2018. Review.

8.

The multiple sclerosis risk allele within the AHI1 gene is associated with relapses in children and adults.

Graves JS, Barcellos LF, Simpson S, Belman A, Lin R, Taylor BV, Ponsonby AL, Dwyer T, Krupp L, Waubant E, van der Mei IAF.

Mult Scler Relat Disord. 2018 Jan;19:161-165. doi: 10.1016/j.msard.2017.10.008. Epub 2017 Oct 14.

PMID:
29409597
9.

Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM.

Martinez-Thompson JM, Snyder MR, Ettore M, McKeon A, Pittock SJ, Roforth MM, Mandrekar J, Mauermann ML, Taylor BV, Dyck PJB, Windebank AJ, Klein CJ.

Muscle Nerve. 2018 Jun;57(6):1000-1005. doi: 10.1002/mus.26051. Epub 2018 Jan 26.

PMID:
29272035
10.

Common genetic variation within miR-146a predicts disease onset and relapse in multiple sclerosis.

Zhou Y, Chen M, Simpson S Jr, Lucas RM, Charlesworth JC, Blackburn N, van der Mei I, Ponsonby AL; Ausimmune/AUSLONG investigators group, Taylor BV.

Neurol Sci. 2018 Feb;39(2):297-304. doi: 10.1007/s10072-017-3177-1. Epub 2017 Nov 10.

PMID:
29127522
11.

A New Method for Targeted and Sustained Induction of Type 2 Diabetes in Rodents.

Premilovac D, Gasperini RJ, Sawyer S, West A, Keske MA, Taylor BV, Foa L.

Sci Rep. 2017 Oct 26;7(1):14158. doi: 10.1038/s41598-017-14114-4.

12.

Systematic Review of Cognitive Function in Euthymic Bipolar Disorder and Pre-Surgical Temporal Lobe Epilepsy.

Bostock ECS, Kirkby KC, Garry MI, Taylor BVM.

Front Psychiatry. 2017 Aug 9;8:133. doi: 10.3389/fpsyt.2017.00133. eCollection 2017. Review.

13.

Complementary and alternative treatments of multiple sclerosis: a review of the evidence from 2001 to 2016.

Claflin SB, van der Mei IAF, Taylor BV.

J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):34-41. doi: 10.1136/jnnp-2016-314490. Epub 2017 Aug 2. Review.

PMID:
28768821
14.

Genetic variation in the gene LRP2 increases relapse risk in multiple sclerosis.

Zhou Y, Graves JS, Simpson S Jr, Charlesworth JC, Mei IV, Waubant E, Barcellos LF, Belman A, Krupp L, Lucas R, Ponsonby AL, Taylor BV; Ausimmmune/AusLong investigators group.

J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):864-868. doi: 10.1136/jnnp-2017-315971. Epub 2017 Jul 24.

PMID:
28739605
15.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

PMID:
28550069
16.

Variation within MBP gene predicts disease course in multiple sclerosis.

Zhou Y, Simpson S Jr, Charlesworth JC, van der Mei I, Lucas RM, Ponsonby AL; AUSLONG Investigators Group, Taylor BV.

Brain Behav. 2017 Mar 9;7(4):e00670. doi: 10.1002/brb3.670. eCollection 2017 Apr.

17.

The Current Status of the Ketogenic Diet in Psychiatry.

Bostock EC, Kirkby KC, Taylor BV.

Front Psychiatry. 2017 Mar 20;8:43. doi: 10.3389/fpsyt.2017.00043. eCollection 2017. Review.

18.

Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression.

Lim CK, Bilgin A, Lovejoy DB, Tan V, Bustamante S, Taylor BV, Bessede A, Brew BJ, Guillemin GJ.

Sci Rep. 2017 Feb 3;7:41473. doi: 10.1038/srep41473.

19.

Association between human herpesvirus & human endogenous retrovirus and MS onset & progression.

Tao C, Simpson S Jr, Taylor BV, van der Mei I.

J Neurol Sci. 2017 Jan 15;372:239-249. doi: 10.1016/j.jns.2016.11.060. Epub 2016 Nov 24. Review.

PMID:
28017222
20.

Multiple Sclerosis impact on employment and income in New Zealand.

Pearson JF, Alla S, Clarke G, Mason DF, Anderson T, Richardson A, Miller DH, Sabel CE, Abernethy DA, Willoughby EW, Taylor BV.

Acta Neurol Scand. 2017 Sep;136(3):223-232. doi: 10.1111/ane.12714. Epub 2016 Nov 28.

PMID:
27891575
21.

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Tao C, Simpson S Jr, van der Mei I, Blizzard L, Havrdova E, Horakova D, Shaygannejad V, Lugaresi A, Izquierdo G, Trojano M, Duquette P, Girard M, Grand'Maison F, Grammond P, Alroughani R, Terzi M, Oreja-Guevara C, Sajedi SA, Iuliano G, Sola P, Lechner-Scott J, Pesch VV, Pucci E, Bergamaschi R, Barnett M, Ramo C, Singhal B, LA Spitaleri D, Slee M, Verheul F, Fernández Bolaños R, Amato MP, Cristiano E, Granella F, Hodgkinson S, Fiol M, Gray O, McCombe P, Saladino ML, Sánchez Menoyo JL, Shuey N, Vucic S, Shaw C, Deri N, Arruda WO, Butzkueven H, Spelman T, Taylor BV; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1343-1349. doi: 10.1136/jnnp-2016-314013. Epub 2016 Nov 3.

PMID:
27810919
22.

Non-Obese Diabetes and Its Associated Factors in an Underdeveloped Area of South China, Guangxi.

Tang Z, Fang Z, Huang W, Liu Z, Chen Y, Li Z, Zhu T, Wang Q, Simpson S, Taylor BV, Lin R.

Int J Environ Res Public Health. 2016 Sep 30;13(10). pii: E976.

23.

The impact of multiple sclerosis severity on health state utility values: Evidence from Australia.

Ahmad H, Taylor BV, van der Mei I, Colman S, O'Leary BA, Breslin M, Palmer AJ.

Mult Scler. 2017 Jul;23(8):1157-1166. doi: 10.1177/1352458516672014. Epub 2016 Oct 3. Erratum in: Mult Scler. 2016 Dec;22(14 ):NP13.

PMID:
27698247
24.

Stressful life events and the risk of initial central nervous system demyelination.

Saul A, Ponsonby AL, Lucas RM, Taylor BV, Simpson S Jr, Valery P, Dwyer T, Kilpatrick TJ, Pender MP, van der Mei IA.

Mult Scler. 2017 Jun;23(7):1000-1007. doi: 10.1177/1352458516667566. Epub 2016 Sep 6.

PMID:
27600112
25.

Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study.

Pan G, Simpson S Jr, van der Mei I, Charlesworth JC, Lucas R, Ponsonby AL, Zhou Y, Wu F, Taylor BV.

J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1204-1211. doi: 10.1136/jnnp-2016-313722. Epub 2016 Aug 24.

PMID:
27559181
26.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF.

Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.

27.

Synergetic and antagonistic effects of combined calcitriol and interferon-β treatment on cytokine production by stimulated PBMCs.

Simpson S Jr, Stewart N, van der Mei I, Blizzard L, Taylor BV.

J Neuroimmunol. 2016 Aug 15;297:148-55. doi: 10.1016/j.jneuroim.2016.05.020. Epub 2016 May 31.

PMID:
27397088
28.

Axonopathy in peripheral neuropathies: Mechanisms and therapeutic approaches for regeneration.

Landowski LM, Dyck PJ, Engelstad J, Taylor BV.

J Chem Neuroanat. 2016 Oct;76(Pt A):19-27. doi: 10.1016/j.jchemneu.2016.04.006. Epub 2016 May 2. Review.

PMID:
27151423
29.

Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.

Mahurkar S, Moldovan M, Suppiah V, Sorosina M, Clarelli F, Liberatore G, Malhotra S, Montalban X, Antigüedad A, Krupa M, Jokubaitis VG, McKay FC, Gatt PN, Fabis-Pedrini MJ, Martinelli V, Comi G, Lechner-Scott J, Kermode AG, Slee M, Taylor BV, Vandenbroeck K, Comabella M, Boneschi FM; Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), King C.

Pharmacogenomics J. 2017 Jul;17(4):312-318. doi: 10.1038/tpj.2016.20. Epub 2016 Mar 22.

PMID:
27001119
30.

Modeling the course and outcomes of multiple sclerosis is statistical twaddle--Yes.

Taylor BV.

Mult Scler. 2016 Feb;22(2):140-2. doi: 10.1177/1352458515625809. No abstract available.

PMID:
26830393
31.

Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis.

Zhou Y, Zhu G, Charlesworth JC, Simpson S Jr, Rubicz R, Göring HH, Patsopoulos NA, Laverty C, Wu F, Henders A, Ellis JJ, van der Mei I, Montgomery GW, Blangero J, Curran JE, Johnson MP, Martin NG, Nyholt DR, Taylor BV; ANZgene consortium.

Mult Scler. 2016 Nov;22(13):1655-1664. Epub 2016 Jan 27.

PMID:
26819262
32.

Disability profile of multiple sclerosis in New Zealand.

Alla S, Pearson JF, Taylor BV, Miller DH, Clarke G, Richardson A, Willoughby E, Abernethy DA, Sabel CE, Mason DF.

J Clin Neurosci. 2016 Jun;28:97-101. doi: 10.1016/j.jocn.2015.09.020. Epub 2016 Jan 4.

PMID:
26765754
33.

Low-density Lipoprotein Receptor-related Proteins in a Novel Mechanism of Axon Guidance and Peripheral Nerve Regeneration.

Landowski LM, Pavez M, Brown LS, Gasperini R, Taylor BV, West AK, Foa L.

J Biol Chem. 2016 Jan 15;291(3):1092-102. doi: 10.1074/jbc.M115.668996. Epub 2015 Nov 23.

34.

An investigation of the relationship between latitude and multiple sclerosis severity in New Zealand.

Alla S, Pearson JF, Taylor BV, Roxburgh R, Clarke G, Miller DH, Richardson A, Abernethy DA, Willoughby E, Sabel CE, Mason DF.

Mult Scler. 2016 Apr;22(5):705-7. doi: 10.1177/1352458515605909. Epub 2015 Oct 2. No abstract available.

PMID:
26432856
35.

A new era in the treatment of multiple sclerosis.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.

Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. Review.

PMID:
26224184
36.

Population attributable fractions and joint effects of key risk factors for multiple sclerosis.

van der Mei I, Lucas RM, Taylor BV, Valery PC, Dwyer T, Kilpatrick TJ, Pender MP, Williams D, Chapman C, Otahal P, Ponsonby AL.

Mult Scler. 2016 Apr;22(4):461-9. doi: 10.1177/1352458515594040. Epub 2015 Jul 21.

PMID:
26199349
37.

A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis.

Gu BJ, Field J, Dutertre S, Ou A, Kilpatrick TJ, Lechner-Scott J, Scott R, Lea R, Taylor BV, Stankovich J, Butzkueven H, Gresle M, Laws SM, Petrou S, Hoffjan S, Akkad DA, Graham CA, Hawkins S, Glaser A, Bedri SK, Hillert J, Matute C, Antiguedad A; ANZgene Consortium, Wiley JS.

Hum Mol Genet. 2015 Oct 1;24(19):5644-54. doi: 10.1093/hmg/ddv278. Epub 2015 Jul 17.

PMID:
26188005
38.

Comparison of precipitating factors for mania and partial seizures: Indicative of shared pathophysiology?

Bostock EC, Kirkby KC, Garry MI, Taylor BV.

J Affect Disord. 2015 Sep 1;183:57-67. doi: 10.1016/j.jad.2015.04.057. Epub 2015 May 11. Review.

PMID:
26001664
39.

Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.

Dyck PJ, Taylor BV, Davies JL, Mauermann ML, Litchy WJ, Klein CJ, Dyck PJ.

Muscle Nerve. 2015 Oct;52(4):488-97. doi: 10.1002/mus.24707. Epub 2015 Aug 13. Review.

40.

The role of epidemiology in MS research: Past successes, current challenges and future potential.

Simpson S Jr, Taylor BV, van der Mei I.

Mult Scler. 2015 Jul;21(8):969-77. doi: 10.1177/1352458515574896. Epub 2015 Mar 12. Review.

PMID:
25767125
41.

Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Mathey EK, Park SB, Hughes RA, Pollard JD, Armati PJ, Barnett MH, Taylor BV, Dyck PJ, Kiernan MC, Lin CS.

J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):973-85. doi: 10.1136/jnnp-2014-309697. Epub 2015 Feb 12. Review.

42.

The co-occurrence of multiple sclerosis and type 1 diabetes: shared aetiologic features and clinical implication for MS aetiology.

Tettey P, Simpson S Jr, Taylor BV, van der Mei IA.

J Neurol Sci. 2015 Jan 15;348(1-2):126-31. doi: 10.1016/j.jns.2014.11.019. Epub 2014 Nov 20. Review.

PMID:
25480016
43.

Vascular comorbidities in the onset and progression of multiple sclerosis.

Tettey P, Simpson S Jr, Taylor BV, van der Mei IA.

J Neurol Sci. 2014 Dec 15;347(1-2):23-33. doi: 10.1016/j.jns.2014.10.020. Epub 2014 Oct 16. Review.

PMID:
25454639
44.

The Scandinavian paradox revisited: Editorial comment on Berg-Hansen et al. 'High prevalence and no latitude gradient of multiple sclerosis in Norway'.

Simpson S Jr, Taylor BV.

Mult Scler. 2014 Nov;20(13):1675-7. doi: 10.1177/1352458514535474. No abstract available.

PMID:
25395546
45.

Modulating effects of WT1 on interferon-β-vitamin D association in MS.

Lin R, Taylor BV, Charlesworth J, van der Mei I, Blizzard L, Stewart N, Ponsonby AL, Dwyer T, Pittas F, Simpson S Jr.

Acta Neurol Scand. 2015 Apr;131(4):231-9. doi: 10.1111/ane.12315. Epub 2014 Oct 14.

PMID:
25312909
46.

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity.

Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, Thompson AJ.

Neurology. 2014 Sep 9;83(11):1022-4. doi: 10.1212/WNL.0000000000000768. No abstract available.

47.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1857-65. doi: 10.1016/j.jocn.2014.01.017. Epub 2014 Jun 30. Review.

PMID:
24993136
48.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1835-46. doi: 10.1016/j.jocn.2014.01.016. Epub 2014 Jun 30. Review.

PMID:
24993135
49.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1847-56. doi: 10.1016/j.jocn.2014.01.018. Epub 2014 Jun 28. Review.

PMID:
24986155
50.

Multiple sclerosis in New Zealand Māori.

Pearson JF, Alla S, Clarke G, Taylor BV, Miller DH, Richardson A, Mason DF.

Mult Scler. 2014 Dec;20(14):1892-5. doi: 10.1177/1352458514535130. Epub 2014 May 22.

PMID:
24852927

Supplemental Content

Loading ...
Support Center